Jump-starting the conversation about harm reduction: making sense of drug effects

City checking: Piloting the UK's first community‐based drug safety testing ( drug checking ) service in 2 city centres

(2020) Fiona Measham   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A simple mechanistic terminology of psychoactive drugs: a proposal

(2020) Roland Seifert et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems

(2018) William E. Fantegrossi et al.   DRUG METABOLISM REVIEWS

The psychostimulant (±)- cis -4,4′-dimethylaminorex (4,4′-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters

(2018) Julian Maier et al.   NEUROPHARMACOLOGY

Characteristics of NPS use in patients admitted to acute psychiatric services in Southeast Scotland: a retrospective cross-sectional analysis following public health interventions

(2017) Kyle H Bennett et al.   BMJ Open

Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats

(2016) Tomáš Páleníček et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Tightrope or Slackline? The Neuroscience of Psychoactive Substances

(2016) Philippe Coulon et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The ‘drug policy ratchet’: why do sanctions for new psychoactive drugs typically only go up?

(2014) Alex Stevens et al.   ADDICTION

MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology

(2013) P. Saez-Briones et al.   Current Neuropharmacology

A proposal for an updated neuropsychopharmacological nomenclature

(2013) Joseph Zohar et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine

(2012) Ornella Corazza et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project

(2012) Paolo Deluca et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The drug effects questionnaire: psychometric support across three drug types

(2012) Meghan E. Morean et al.   PSYCHOPHARMACOLOGY

Aminoindanes-the next wave of ‘legal highs’?

(2011) P.D. Sainsbury et al.   Drug Testing and Analysis

‘Heads Held High’: An Exploratory Study of Legal Highs in Pre-Legislation Ireland

(2011) Marie Claire Van Hout et al.   JOURNAL OF ETHNICITY IN SUBSTANCE ABUSE

Is Ecstasy an “Empathogen”? Effects of ±3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others

(2010) Gillinder Bedi et al.   BIOLOGICAL PSYCHIATRY

Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls

(2010) Ines Möller et al.   Drug Testing and Analysis

Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues

(2010) Fabrizio Schifano et al.   PSYCHOPHARMACOLOGY

Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study

(2009) Celia J. A. Morgan et al.   ADDICTION

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain

(2009) Jeremy R. Johnson et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT